Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge
During this session, our speakers Philippe de Jong and Kirian Claeyé will discuss the interesting judgment of the General Court in Polpharma v. EMA.
Our speakers will explain the judgment’s impact on whether a new medicinal product is entitled to a separate initial marketing authorisation, or belongs to the same global marketing authorisation as an earlier medicinal product. In other words, can the new medicinal product benefit from its own regulatory data protection period or not?
The judgment is furthermore not only interesting from a substantive point of view, but also contains some interesting examples on the pitfalls that may arise under EU procedural law in challenging decisions from the European Commission, whether in this area or others.
Recommended articles
Belgian Parliament has adopted urgent 2026 healthcare budget measures: what’s the impact on the pharma industry?
Over the Christmas break, the Belgian Parliament adopted an urgent law with several measures linked to the approved 2026 healthcare budget, with effect from 1 January 2026. The law is intentionally limited to provisions that must enter into force immediately to ensure that the required savings and revenues are available from the start of the […]
Read on
EU Reaches Pharma Package Deal: Key Changes at a Glance
On 11 December 2025, following overnight negotiations, the Council and the European Parliament announced a political agreement on the long-awaited Pharma Package (see here). The reform seeks to update the EU’s pharmaceutical rulebook to facilitate access to safe and affordable treatments and bolster the life sciences sector’s competitiveness. While more detailed information is still trickling […]
Read on
Belgian Constitutional Court strikes down pharma industry ‘unavailability contribution’
The Belgian Constitutional Court (“CC”), on 6 November 2025, annulled some provisions of the Law of 18 May 2024 containing various provisions on health and finance, striking down the pharma industry ‘unavailability contribution’. Background Parts of the above Law sought to protect patients from bearing additional costs when reimbursable medicines become unavailable and must be […]
Read on